Regulus Therapeutics Inc - RGLS Company Cash Volume

Corporate emblem and logo of Regulus Therapeutics Inc. (RGLS)

The lack of pricing power during the RNA drug testing phase is confirmed by the trend in cash on hand, where 0.06 reflects the latest metric value. However, fixed R&D costs and future FDA patents will provide powerful operating leverage. The secure US perimeter and the humanitarian status of medicine fully shield Regulus Therapeutics (RGLS) developments from geopolitical risks.

Regulus - RGLS Company Cash Volume (period 07/04/2022 - 07/05/2025)

Analytical breakdowns and data insights for company Regulus Therapeutics Inc. (RGLS)

- stock value and consensus price forecast:
- cash position and cash flow details:
Fundamental company analysis:RGLS regulusrx.com
Brand item of regulusrx.com

Defensive assets are selected based on the criterion of high operational resilience. Regulus Therapeutics (RGLS) meets this standard by funding complex developments in RNA interference and DNA therapy. This metric captures the absolute volume of liquid assets on the issuer's accounts, excluding temporary reporting gaps. By analyzing the cash reserve trend, an investor assesses the company's ability to maintain research autonomy. Excess capital minimizes default risk but may reduce overall portfolio returns.

Main competitors

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash on Hand 4DMT (FDMT)|Company Cash Volume LXEO|Company Liquid Assets Korro Bio Inc.|Company Cash Volume EDIT (Editas Medicine Inc)|SLN: Company Cash and Cash Equivalents|PRQR - Company Cash Funds|Company Liquid Assets codexis.com CDXS|SGMO: Company Cash Volume|Nautilus Biotechnology (NAUT) - Company Cash Volume|Company Cash Funds Metagenomi, Inc|precisionbiosciences.com (DTIL) - Company Liquid Assets|Company Cash Funds Generation Bio Co. (GBIO)|Company Liquid Assets Boundless Bio, Inc.|Company Cash Funds Exicure, Inc. XCUR|IMNN: Company Cash and Cash Equivalents|PHIO - Company Cash Funds|Company Liquid Assets Mustang Bio MBIO|RNAZ: Company Cash Volume|Company Cash Position Bionano Genomics Inc. BNGO|APDN (Applied DNA Corp) - Company Cash Volume|bluebirdbio.com (BLUE) - Company Liquid Assets|Company Cash Volume IPA|Company Cash Volume Omega (OMGA)|Company Cash Funds Singular Genomics Systems Inc OMIC|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume